CorMedix Therapeutics will announce its financial results for the first quarter ending March 31, 2026, before market open on May 14, 2026. The company will also host a corporate update conference call at 8:30 AM Eastern Time on the same day. CorMedix focuses on developing and marketing therapeutic products for serious diseases in the U.S., particularly in institutional healthcare settings. This update follows recent positive clinical trial results, highlighting the company's ongoing progress.
Polaris Inc. reported a strong quarterly performance with earnings per share of $1.97, beating estimates by over 155%, and revenues of $2.02 billion, up 9.2% year-over-year. The growth was driven by sales recovery in the utility off-road vehicle segm...
Seagate Technology is set to report its Q2 2026 earnings with analysts expecting an EPS of $5.10 and revenue around $3.5 billion, reflecting strong demand for data storage driven by AI growth. The company's optimistic guidance aligns with these estim...
Teladoc Health, a leader in virtual healthcare services, has seen its average analyst price target rise from $8.35 to $11.00, reflecting increased confidence in its market position. The stock recently jumped 6.1% with high trading volume, driven by r...
Procter & Gamble, a leading consumer goods company and Dividend King, is seeing a decline in analyst price targets from $162.52 to $152 over the past year, though Deutsche Bank remains optimistic with a $177 target. Despite a strong history of beatin...
Cognizant Technology Solutions has seen a decline in analyst price targets from $74.94 to $56.33 over the past year, reflecting increased caution about its stock performance. Despite this, some analysts remain optimistic, with a notable price target ...
